人工器官市场－全球产业规模、份额、趋势、机会及预测（依器官类型、类型、材料类型、地区及竞争格局划分，2021-2031年）

全球人造器官市场预计将从 2025 年的 305.5 亿美元成长到 2031 年的 541.5 亿美元，年复合成长率为 10.01%。

这些人工装置对于模拟衰竭的自身器官（例如心臟、肝臟和肾臟）的生理功能至关重要。推动这一市场发展的关键因素包括全球捐赠器官的严重短缺以及导致终末期器官衰竭的慢性疾病的增加。此外，全球人口老化导致器官退化速度加快，使得在无法进行生物移植的情况下，人们更需要机械解决方案来维持生命。

然而，该产业面临许多重大障碍，包括严格的监管流程和高昂的研发成本，这些都会延缓产品进入市场。这些障碍限制了创新医疗设备惠及病患的速度。供体器官供应与患者需求之间持续存在的缺口凸显了这些技术的迫切需求。根据器官取得与移植网络（OPTN）预测，到2024年，美国国家器官移植等待名单上的候选人将超过10万人，这表明人工技术必须填补生物器官短缺的关键缺口。

市场驱动因素

推动全球人工器官市场发展的关键因素是捐赠器官严重短缺和移植等待名单过长。随着心臟衰竭和肾衰竭等慢性疾病发病率的不断上升，有限的生物器官供应与巨大的需求之间的差距持续扩大。这种供需失衡不可避免地增加了对人工器官的需求，人工器官既可作为最终治疗方法，也可作为移植前的过渡方案。美国卫生资源与服务管理局 (HRSA) 2025 年 1 月的数据也印证了供应紧张的严峻情况。数据显示，2024 年美国医疗系统仅进行了 27,759 例肾臟移植手术，远远无法满足庞大的肾臟替代治疗患者群体的需求。这迫使临床医生依赖机械辅助系统来挽救患者的生命。

同时，3D生物列印技术和生物相容性材料的快速发展，透过提升设备的安全性和功能性，加速了市场扩张。利用钛、生物列印支架和磁浮技术的创新已成功降低了排斥率并提高了耐用性。 2024年7月，德克萨斯心臟研究所宣布了一项突破性进展：全球首例BiVACOR全人工心臟在FDA早期可行性研究中成功植入人体。这些技术进步正带来商业性的成功。例如，2025年1月，Carmat公司报告称，其Ayson人工心臟2024年的年销售额达到700万欧元，比前一年增长了2.5倍，标誌着该产品已从实验原型过渡到可行的商业解决方案。

市场挑战

全球人工器官市场的成长受到巨额资金需求和严格法规结构的限制。开发这些维生设备需要复杂的工程技术和广泛的安全测试，导致研发週期漫长，抑制了投资并延缓了商业化。临床试验和监管审查的高昂成本造成了“资金筹措缺口”，使得许多前景广阔的技术在实现商业化之前就因缺乏资金而失败。因此，企业被迫对其产品收取高价，限制了其在註重成本的医疗保健系统中的普及和应用。

这些延误最明显地体现在监管部门核准和实际报销之间的滞后，而这实际上决定了产品是否能进入市场。根据先进医疗技术协会（AdvaMed）的数据，2024年，获得FDA批准的新医疗技术获得联邦医疗保险（Medicare）报销的平均等待时间约为5.7年。这种长期的不确定性阻碍了製造商快速惠及患者，导致大多数用户因缺乏报销而无法负担昂贵的治疗，最终抑制了市场成长并减缓了创新週期。

市场趋势

携带式穿戴式人工肾臟设备的兴起正在改变肾臟护理领域，这些设备消除了传统血液透析带来的行动不便。这一趋势致力于研发轻巧紧凑的系统，在实现持续血液净化的同时，让患者能够维持积极的生活方式，从而显着提高生活品质。这些创新突破了固定临床基础设施的限制，提供以患者为中心的居家解决方案，模拟患者自身肾臟的持续过滤功能。例如，Medindia 于 2024 年 11 月报道，AWAK Technologies 已启动一项关键性临床试验前期的可穿戴腹膜透析设备，该设备重量仅为 3 公斤，旨在让患者摆脱频繁前往诊所接受治疗的困扰。

同时，融合物联网 (IoT) 和人工智慧的即时设备监控正在革新人工器官系统的管理和最佳化。业界领导企业正利用先进的演算法预测併发症、远端监测患者健康指标并制定个人化治疗方案，从而减轻医疗机构的负担。这种数位转型使机械辅助系统能够动态适应生理变化，延长设备使用寿命并提高病患安全。费森尤斯医疗 (Fresenius Medical Care) 于 2024 年 11 月宣布，其人工智慧驱动的贫血管理模式入选美国医疗保险和医疗补助服务中心 (CMS) 的人工智慧演示日，充分体现了这一趋势，凸显了智慧软体在推进肾臟替代疗法方面日益受到重视。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球人工器官市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依器官类型（人工心臟、人工肾臟、人工胰臟、人工肺、其他）
  • 依类型（机械式、生物力学式、生物学式）
  • 依材料类型（无机聚合物、无机聚合物和活细胞、仅活细胞）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美人工器官市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲人工器官市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区人工器官市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲人工器官市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲人工器官市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球人工器官市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• SynCardia
• Carmat
• Abbott
• Medtronic
• Fresenius Medical Care
• NxStage
• Terumo
• Boston Scientific
• APL
• Nipro

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Artificial Organs Market is projected to expand from USD 30.55 Billion in 2025 to USD 54.15 Billion by 2031, reflecting a CAGR of 10.01%. These engineered devices are essential for mimicking the physiological duties of failing natural organs like the heart, liver, or kidneys. Key factors fueling this market include a critical worldwide scarcity of donor organs and a growing prevalence of chronic illnesses that lead to end-stage organ failure. Furthermore, aging global populations are experiencing higher rates of organ degeneration, increasing the need for mechanical solutions to sustain life when biological transplants are not an option.

However, the industry faces substantial hurdles due to stringent regulatory processes and exorbitant development costs that slow down market entry. These obstacles limit how quickly innovative devices can become available to patients. The pressing need for these technologies is highlighted by the continuing gap between the supply of donors and patient demand. According to the Organ Procurement and Transplantation Network, over 100,000 candidates were on the national transplant waiting list in the United States in 2024, demonstrating the vital gap artificial technologies must fill to mitigate the shortage of biological alternatives.

Market Driver

The primary force behind the Global Artificial Organs Market is the acute shortage of human donor organs combined with lengthening transplant waiting lists. As the incidence of chronic conditions like cardiac and renal failure rises, the gap between the limited availability of biological organs and the massive demand continues to grow. This disparity necessitates engineered alternatives acting as either destination therapies or bridges to transplantation. The severity of supply constraints is underscored by data from the Health Resources and Services Administration in January 2025, which noted that the U.S. healthcare system performed only 27,759 kidney transplants in 2024-a number insufficient to meet the needs of the large patient population requiring renal replacement, forcing clinicians to rely on mechanical support systems to prevent mortality.

Simultaneously, rapid progress in 3D bioprinting and biocompatible materials is accelerating market expansion by improving device safety and function. Innovations utilizing titanium, bio-printed scaffolds, and magnetic levitation are successfully lowering rejection rates and enhancing durability. A major breakthrough was reported by The Texas Heart Institute in July 2024, announcing the first-in-human implantation of the BiVACOR Total Artificial Heart during an FDA early feasibility study. Such technological strides are translating into commercial success; for example, Carmat reported in January 2025 that annual sales for its Aeson artificial heart reached €7 million in 2024, a 2.5-fold increase over the prior year, marking a transition from experimental prototypes to viable commercial solutions.

Market Challenge

High capital requirements and rigorous regulatory frameworks stand as significant barriers to the growth of the Global Artificial Organs Market. The development of these life-sustaining devices necessitates intricate engineering and extensive safety testing, resulting in prolonged timelines that discourage investment and delay commercial release. The substantial financial cost of clinical trials and regulatory reviews creates a "valley of death," causing many promising technologies to fail due to a lack of funding before generating revenue. Consequently, companies are often forced to set premium prices for their products, which restricts adoption and accessibility within cost-conscious healthcare systems.

These delays are notably apparent in the lag between regulatory clearance and actual reimbursement, which essentially defines market entry. According to the Advanced Medical Technology Association (AdvaMed), the median wait time for a Medicare coverage decision on a new FDA-cleared medical technology was approximately 5.7 years in 2024. This extended period of uncertainty prevents manufacturers from reaching patients quickly, as the lack of insurance coverage makes these expensive therapies unaffordable for most users, ultimately hindering market growth and slowing innovation cycles.

Market Trends

The renal care landscape is being transformed by the rise of portable and wearable artificial kidney devices, which address the mobility constraints of traditional hemodialysis. This trend emphasizes the creation of lightweight, compact systems that enable continuous blood purification while allowing patients to maintain active lifestyles, thereby vastly enhancing their quality of life. Moving beyond stationary clinical infrastructure, these innovations offer patient-centric, home-based solutions that replicate the natural kidney's continuous filtration. For instance, Medindia reported in November 2024 that AWAK Technologies began a pre-pivotal clinical trial for a wearable peritoneal dialysis device weighing just 3 kilograms, aiming to provide patients with greater freedom from clinic-based treatments.

Concurrently, the incorporation of the Internet of Things (IoT) and artificial intelligence for real-time device monitoring is revolutionizing the management and optimization of artificial organ systems. Industry leaders are utilizing advanced algorithms to predict complications, remotely monitor patient health markers, and personalize treatment plans, reducing the strain on healthcare facilities. This digital shift ensures mechanical support systems can dynamically adapt to physiological changes, improving device longevity and patient safety. Highlighting this trend, Fresenius Medical Care announced in November 2024 that its AI-powered Anemia Control Model was selected for the Centers for Medicare & Medicaid Services AI Demo Days, demonstrating the increasing dependence on intelligent software to enhance renal replacement therapies.

Key Market Players

• SynCardia
• Carmat
• Abbott
• Medtronic
• Fresenius Medical Care
• NxStage
• Terumo
• Boston Scientific
• APL
• Nipro

Report Scope

In this report, the Global Artificial Organs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Organs Market, By Organ Type

• Artificial Heart
• Artificial Kidney
• Artificial Pancreas
• Artificial Lungs
• Others

Artificial Organs Market, By Type

• Mechanical
• Biomechanical
• Biological

Artificial Organs Market, By Material Type

• Inanimate Polymers
• Combination of Inanimate Polymers & Living Cells
• Only Living Cells

Artificial Organs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Organs Market.

Available Customizations:

Global Artificial Organs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Artificial Organs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Organ Type (Artificial Heart, Artificial Kidney, Artificial Pancreas, Artificial Lungs, Others)
  • 5.2.2. By Type (Mechanical, Biomechanical, Biological)
  • 5.2.3. By Material Type (Inanimate Polymers, Combination of Inanimate Polymers & Living Cells, Only Living Cells)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Artificial Organs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Organ Type
  • 6.2.2. By Type
  • 6.2.3. By Material Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Artificial Organs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Organ Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Material Type
  • 6.3.2. Canada Artificial Organs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Organ Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Material Type
  • 6.3.3. Mexico Artificial Organs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Organ Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Material Type

7. Europe Artificial Organs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Organ Type
  • 7.2.2. By Type
  • 7.2.3. By Material Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Artificial Organs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Organ Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Material Type
  • 7.3.2. France Artificial Organs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Organ Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Material Type
  • 7.3.3. United Kingdom Artificial Organs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Organ Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Material Type
  • 7.3.4. Italy Artificial Organs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Organ Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Material Type
  • 7.3.5. Spain Artificial Organs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Organ Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Material Type

8. Asia Pacific Artificial Organs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Organ Type
  • 8.2.2. By Type
  • 8.2.3. By Material Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Artificial Organs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Organ Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Material Type
  • 8.3.2. India Artificial Organs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Organ Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Material Type
  • 8.3.3. Japan Artificial Organs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Organ Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Material Type
  • 8.3.4. South Korea Artificial Organs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Organ Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Material Type
  • 8.3.5. Australia Artificial Organs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Organ Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Material Type

9. Middle East & Africa Artificial Organs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Organ Type
  • 9.2.2. By Type
  • 9.2.3. By Material Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Artificial Organs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Organ Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Material Type
  • 9.3.2. UAE Artificial Organs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Organ Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Material Type
  • 9.3.3. South Africa Artificial Organs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Organ Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Material Type

10. South America Artificial Organs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Organ Type
  • 10.2.2. By Type
  • 10.2.3. By Material Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Artificial Organs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Organ Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Material Type
  • 10.3.2. Colombia Artificial Organs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Organ Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Material Type
  • 10.3.3. Argentina Artificial Organs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Organ Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Material Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Artificial Organs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. SynCardia
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Carmat
• 15.3. Abbott
• 15.4. Medtronic
• 15.5. Fresenius Medical Care
• 15.6. NxStage
• 15.7. Terumo
• 15.8. Boston Scientific
• 15.9. APL
• 15.10. Nipro

16. Strategic Recommendations

17. About Us & Disclaimer